ACCC COVID-19 Resource Center & Discussion Group
for Insights on Providing Optimal Patient Care During the Pandemic.
Providing a VOICE for Arizona's MULTIDISCIPLINARY CANCER CARE TEAMS and the PATIENTS THEY SERVE since 1991
Meetings & Education
TACOS 2020 Summer Conference Highlights
Articles and Blogs
Patient Advocacy Organizations
State & Federal Resources
Find a Clinical Trial
Become a Corporate Member
Industry News Archive
COVID-19 Featured Resources
FDA Approves Expanded Indication of Pembrolizumab for R/R cHL
On October 15, 2020, the U.S. Food and Drug Administration (FDA) approved an expanded label for Keytruda
® (pembrolizumab) as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL). Keytruda is the first anti-PD-1 therapy approved for adult patients with relapsed or refractory cHL after frontline therapy.
Merck's press release